期刊文献+

前列腺癌组织中CXCR7与Ki67的表达及相关性研究 被引量:1

Expression and Correlation of CXCR7 and Ki67 in Prostatic Cancer
下载PDF
导出
摘要 目的:研究趋化因子受体CXCR7与细胞增殖指数Ki67在前列腺癌组织及良性前列腺增生组织中的表达水平及相关性。方法:应用免疫组织化学检测83例前列腺癌组织及40例良性前列腺增生组织中CXCR7与Ki-67的表达。结果:CXCR7和Ki67在前列腺癌标本中的阳性表达率分别为61.4%和69.9%,在良性前列腺增生组织中的表达率分别为17.5%和10.0%,CXCR7和Ki-67在前列腺癌组织中的表达呈正相关,差异具有统计学意义(P<0.05)。结论:CXCR7可能参与了细胞周期的调控,促进前列腺癌的发生、发展,对前列腺癌的诊断和治疗具有指导意义。 Objective:To study the CXCR7 and Ki67 expression and their correlation of them in prostatic cancer. Methods:The expression of CXCR7 and Ki67 was detected in 83 cases with prostatic cancer and in 40 cases with benign prostatic hyperplasia by the immunohistochemistry. Results:CXCR7 and Ki67 expression in the cases with prostatic cancer were 61.4% (51/83) and 69.9% (58/83), which were obviously higher than those in the cases with benign prostatic hyper-plasia 17.5% (7/40) and 10% (4/40) (P〈0.05).The expression of CXCR7 and Ki67 were coincident in prostatic cancer (P〈0.05). Conclusions:CXCR7 might take part in cell cycle control, so as to promote the occurrence and development of prostate cancer, and could have the guiding significance in its diagnosis and treatment of it.
出处 《交通医学》 2014年第5期445-448,共4页 Medical Journal of Communications
关键词 前列腺癌 CXCR7 KI67 免疫组织化学法 prostatic cancer CXCRT Ki67 immunohistochemistry
  • 相关文献

参考文献11

  • 1Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide bur- den of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010,127(12) : 2893-2917.
  • 2Melchionna R,Di Carlo A,De Mori R,et al. Induction of myogenic differentiation by SDF-1 via CXCR4 and CXCR7 receptors [ J ]. Muscle Nerve, 2010,41 (6) : 828-835.
  • 3林海利,郑周达,陈森期,许振强,庄志明,张朝贤,邹宗楷,沈洪武.前列腺癌组织Ki-67表达及其临床意义的研究[J].中华肿瘤防治杂志,2007,14(23):1805-1806. 被引量:11
  • 4Singh AK,Arya RK,Trivedi AK,et al. Chemokine receptortrio:CXCR3,CXCR4 and CXCR7 erosstalk via CXCLll and CXCL12 [ J ]. Cytokine Growth Factor Rev, 2013,24 ( 1 ) : 41 - 49.
  • 5Sfnehez-Martin L,S6nchez-Mateos P, Cab aiias C. CXCR7 impact on CXCL12 biology and disease[J].Trends Mol Med, 2013,19( 1 ) : 12-22.
  • 6Xue TC, Chen RX, Han D, et al. Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocel- lular carcinoma cells with highly metastatic potential [J]. Exp Ther Med, 2012,3 ( 1 ) : 117-123.
  • 7Zheng K,Li HY,Su XL,et al. Chemokine receptor CXCR7 regulates the invasion,angiogenesis and tumor growth of hu- man hepatocellular carcinoma cells [ J ]. J Exp Clin Cancer Res, 2010,29: 31.
  • 8Rajagopal S,Kim J,Ahn S,et al. β-arrestin-but not G pro- tein-mediated signaling by the"decoy"receptor CXCR7 [J]. Proceedings of the National Academy of Sciences,2010, 107 (2) : 628-632.
  • 9Kovaes JJ, Hara MR, Davenport CL, et al. Arrestin develop- ment: emerging roles for beta-arrestins in developmental sig- naling pathways[J]. Dev Ce11,2009,17(4):443-458.
  • 10Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion,and tumor development [ J]. J Exp Med, 2006,203(9) : 2201-2213.

二级参考文献7

  • 1周虹,杨竹,蔡汉钟,王芳.Ki67抗原在卵巢肿瘤组织中的表达及意义[J].重庆医学,2005,34(2):252-253. 被引量:11
  • 2Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immund, 1984,13(3) : 1710-1715.
  • 3Tut V M, Braithwaite K L, Angus B, et al. Cyclin D1 expression in transitional cell cacinorna of the bladder: correlation with p53, wsfl, pRb and Ki-67[J]. Br J Cancer,2001,84(2):270-275.
  • 4David G B, John N E. Urologic surgical pathology[J]. Mosby Baston, 1998, 32(6) :351-356.
  • 5Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J]. Int J Cancer, 1983,31(1) :13-20.
  • 6Charpin C, Dicaire M J, Barbeau B, et al. Monoclonal 3C6F9 distribution in human breast carcinomas:image cytometry of immunocytochemical assays[J]. Med Oncol Tumor Pharmacother, 1991,8(4) :243-251.
  • 7Claudio P P, Zamparelli A, Garcia F U, et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27 ( kipl ), p53, mdm-2, and Ki-67(MIB-1) in prostatic gland adenocarcinoma[J]. Clin Cancer Res, 2002, 8(6):1808.

共引文献10

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部